GU SHEISTY

@Bio_comunidad When the peptide vendor sends you fetty labeled as mots-c.

Un error de etiquetado en un suplemento para aves terminó en tragedia: 42 búhos murieron por una sobredosis extrema de vitamina B6. La dosis real era miles de veces mayor a la indicada, provocando daño neurológico fatal en los aves.

Everytime a 20 year old broccoli head says "Mitochondria" in a TikTok video, an angel loses it's wings.

Today’s Presidential Executive Order on #psychedelics marks a major milestone in the history of these valuable substances. It corrects a fundamental mistake made in 1970, when President Nixon established the Controlled Substances Act (CSA) and classified psychedelics as Schedule I substances - a designation that had no basis. For largely political reasons, these highly promising compounds were pushed out of the medical realm and into illegality. Now, they are coming back - with force. The executive order is directing the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Department of Justice and other federal agencies to reduce the red tape and restrictions that have long stymied researchers and biotech companies in the field. As a result, I expect drug approval processes to accelerate and become less costly. I am very proud that @ataibeckley is at the forefront of this field, with one of the broadest pipelines in psychedelics, including clinical programs focused on DMT, 5-MeO-DMT, R-MDMA and – as previously disclosed - ibogaine and additional novel, discovery compounds in various stages of preclinical development. Since I founded AtaiBeckley in 2017, and seed-funded @COMPASSPathway that same year, these two companies have raised more than $1.5 billion to advance clinical research and development of psychedelic therapies. As access to capital was limited early on - since most investors dismissed the idea as crazy - I invested over $100 million of my own capital and have never sold a single $ATAI share (nor do I intend to). The public sentiment around psychedelics as FDA-regulated drugs has gone from “this is a crazy idea that will ruin your career” to being on the verge of what the market anticipates will be the first regulatory approval of a psychedelic with COMP360… all in less than a decade. What a journey. But we are still only at the beginning. I strongly believe the world will benefit from the full spectrum of psychedelic compounds that demonstrate medical and commercial value. I also believe that delivery mechanisms and treatment duration are critical, as these therapies must fit within the commercial realities and infrastructure of the U.S. and global healthcare systems. That conviction is exactly why AtaiBeckley has built such a broad and diversified pipeline with a focus on short-acting psychedelics: x.com/C_Angermayer/s… Once approved, I expect physicians will determine which treatments are best suited to specific patient profiles. Over time, better data and real-world evidence will significantly improve this matching - delivering the right FDA-approved treatment to the right patient. This level of presidential attention also reinforces another long-held belief of mine: the support – and potential use - for psychedelic therapies is far larger and broader than most people have historically assumed. Take once more AtaiBeckley as an example. Most analysts currently model compounds like BPL-003 and VLS-01 primarily within treatment-resistant depression (TRD) - patients who have already failed at least two antidepressant treatments. But my own personal view (and ultimate vision) would be to progress to these treatments sooner, especially when existing treatments often have limited efficacy and significant side effects. Given the favorable safety profiles and promising efficacy of psychedelics we are seeing in the clinical trials run to date, and based on my own extensive discussions with therapists who have worked with these compounds, I personally believe psychedelic therapies have the potential to become first-line treatments - and, over time, even potentially play a role in prevention. Thank you, @realDonaldTrump, for today’s important signal of support, and @joerogan for driving it! Most importantly, thank you to everyone working behind the scenes to make this possible today - and to the fellow drug developers advancing these therapies. This has been, and will continue to be, a truly collaborative effort. You can all be proud of the meaningful difference you are about to make for the millions of patients in need.

At the forefront of AI means supporting new primitives early. Proud to be AIKEK’s first official integration as AI evolution environments begin. How it works 👇

The moment we've all been waiting for is finally here 🤖 If you're running an agent, you absolutely need to take a look!

@kloss_xyz @sama Methos

@sama what’s OpenAI’s answer to Mythos Sam?

To celebrate 3 million weekly codex users, we are resetting usage limits. We will do this every million users up to 10 million. Happy building!

@based16z you haven’t felt truly free until you’ve ordered powders in vials from a random website, mixed it with bacteriostatic water you ordered on Amazon, and injected it into your body MURCAH

@bridgemindai I'm here for it.

Claude Code rate limited me so hard I bought a $5,000 NVIDIA DGX Spark. Arriving tomorrow. A personal AI supercomputer. Anthropic cut off OpenClaw users. Slashed Claude Opus 4.6 rate limits. Told $200/month Max plan customers to use less. Then gave us a credit as an apology. This is what happens when AI companies have too much power over your workflow. One update and your entire stack breaks. Local models are the only infrastructure no one can throttle. No rate limits. No 529 errors. No surprise policy changes. Tomorrow I'm testing the DGX Spark live on stream. Running local models through real vibe coding workflows. The goal is simple. Never depend on a single provider again.

"Vibecoders" around the world this week.

@vnicolici I've never hit session limits on Pro 200.. Usually get to the end of the week with 10-15% to spare. This week was the first I had to actually change my workflow to make it through, though.

@sheisty Imagine you used your session limit in 3 hours, and you ended up with a large context. So, you wait for 2 hours for the session limit to reset, meanwhile the cache expires after 1 hour, and when you ask it "continue" it instantly reprocesses a large context. Not ideal.

Claude Pro/Max users burning through sessions in hours? Anthropic’s official response to SessionGate: → Don’t use Opus (the one you paid for) → Don’t use 1M context (even though it’s default) → Never resume large sessions after 1hr “You’re holding it wrong.”

@kanavtwt Brainstorm and create spec / handoff prompt with Opus, switch to Sonnet to handle biz.

with Sonnet 4.6 atleast I get a couple hours of work before hitting limits, but with Opus it’s literally 2 prompts on the $20 plan like wtf

Either way, I'm gonna need to see some receipts from these cats saying they hit their Claude Code Pro limits on a single new session prompt.. Jussie Smollett type beat 😆

Anthropic: "You're holding it wrong." x.com/sheisty/status…

Thank you to everyone who spent time sending us feedback and reports. We've investigated and we're sorry this has been a bad experience. Here's what we found:

NGMI

"You're holding it wrong" x.com/sheisty/status…

We need to talk about the Claude Code rate limits

@devneeddev x.com/sheisty/status…

Here's the most transparent test that Claude Code's scam 👇 After this announcement, for just testing, I bought $50 credit because my Max Plan had hit the weekly limits. I just made two code reviews (not complex) by updating Claude Code with Sonnet 4.6 (NOT OPUS) and a fresh session ; it directly consumed ~$20. But the more strange thing is that I used an API key for exactly the same code review by using OpenCode (Opus 4.6 Max effort), and it only consumed $5.30 (OpenCode findings were more detailed). Anthropic is just a scam now; it is disappointing and doesn't deserve any money. Simply, I am quitting until they give us an explanation. Also, a note, they are not refunding anything even you prove there is a bug, and they are consuming your credits! I'm also sharing my feedback IDs. Maybe you can really figure out what you've done wrong. You are just losing your promoters and community! - Feedback ID: 1d22e80f-f522-4f03-a54e-3a6e1a329c49 - Feedback ID: 84dbb7c9-6b69-4c00-8770-ce5e1bc64715 @AnthropicAI @claudeai !

@morellifit @harbdarko @Biomaxxer0 Snorting Methyline Blue 😆😆😆

@harbdarko @Biomaxxer0 Modafinil Bromantane Semax (nasal spray - focus) Selank (nasal spray - calm) Nicotine (2-4mg) These are my favorite nootropics (not all at once, just the list of what I use / cycle) And…this, which you snort.

If you're a man over 30, this peptide stack is non-negotiable: - BPC-157 and TB-500 for recovery - Semax and Selank for cognition - Retatrutide and Tirze for body composition Each peptide has a job. None are magic, though. You still have to do the work.

@grichadev source code gets leaked 😭